Article
A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations.
Cell reports - 27 Jul 2021
Bertoglio Federico, Fühner Viola, Ruschig Maximilian, Heine Philip Alexander, Abassi Leila, Klünemann Thomas, Rand Ulfert, Meier Doris, Langreder Nora, Steinke Stephan, Ballmann Rico, Schneider Kai-Thomas, Roth Kristian Daniel Ralph, Kuhn Philipp, Riese Peggy, Schäckermann Dorina, Korn Janin, Koch Allan, Chaudhry M Zeeshan, Eschke Kathrin, Kim Yeonsu, Zock-Emmenthal Susanne, Becker Marlies, Scholz Margitta, Moreira Gustavo Marçal Schmidt Garcia, Wenzel Esther Veronika, Russo Giulio, Garritsen Hendrikus S P, Casu Sebastian, Gerstner Andreas, Roth Günter, Adler Julia, Trimpert Jakob, Hermann Andreas, Schirrmann Thomas, Dübel Stefan, Frenzel André, Van den Heuvel Joop, Čičin-Šain Luka, Schubert Maren, Hust Michael
Abstract excerpt
The novel betacoronavirus severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) causes a form of severe pneumonia disease called coronavirus disease 2019 (COVID-19). To develop human neutralizing anti-SARS-CoV-2 antibodies, antibody gene libraries from convalescent COVID-19 patients were constructed and recombinant antibody fragments (scFv) against the receptor-binding domain (RBD) of the spike protein...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.